Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant ...

After hours: January 3 at 5:53:27 PM EST Loading Chart for TAK ...

Evox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, snaring an $882 million partnership with Takeda for up to five rare disease programmes. The alliance ...

Visit a quote page and your recently viewed tickers will be displayed here.

Takeda's HYQVIA is the first facilitated subcutaneous immunoglobulin therapy approved in Japan for agammaglobulinemia. HYQVIA offers less frequent dosing (every 3-4 weeks), improving patient ...

Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502), announced it is working with the European Medicines Agency (EMA) to voluntarily withdraw the marketing authorization of Alofisel ...

OSAKA, Japan and CAMBRIDGE, MA, USA I December 13, 2024 I Takeda (TSE:4502/NYSE:TAK) today announced that the company is working with the European Medicines Agency (EMA) to voluntarily withdraw the ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant ...

TOKYO -- As Takeda Pharmaceutical readies new drugs expected to generate billions of dollars in revenue, recent staff and R&D cutbacks have raised questions about the future of its pipeline.

We found the best chef's knives for making paper thin slices. You can get by with a chef's knife for more than a couple of years if you maintain it well and sharpen it periodically. Of course ...

Takeda has bolstered its neuroscience pipeline by licensing drug candidates from California biotech AcuraStem targeting PIKfyve, which is gathering attention as a drug target in amyotrophic ...